ZA200809284B - Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders - Google Patents
Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disordersInfo
- Publication number
- ZA200809284B ZA200809284B ZA200809284A ZA200809284A ZA200809284B ZA 200809284 B ZA200809284 B ZA 200809284B ZA 200809284 A ZA200809284 A ZA 200809284A ZA 200809284 A ZA200809284 A ZA 200809284A ZA 200809284 B ZA200809284 B ZA 200809284B
- Authority
- ZA
- South Africa
- Prior art keywords
- isopropoxypyridin
- penten
- amine
- methyl
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/65—One oxygen atom attached in position 3 or 5
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US74682106P | 2006-05-09 | 2006-05-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200809284B true ZA200809284B (en) | 2009-08-26 |
Family
ID=38441430
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200809284A ZA200809284B (en) | 2006-05-09 | 2008-10-29 | Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders |
Country Status (29)
Country | Link |
---|---|
US (3) | US8461344B2 (es) |
EP (2) | EP2021326A1 (es) |
JP (1) | JP4477097B2 (es) |
KR (1) | KR20090005369A (es) |
CN (1) | CN101472893A (es) |
AR (1) | AR060786A1 (es) |
AU (1) | AU2007249485B2 (es) |
BR (1) | BRPI0709781A2 (es) |
CA (1) | CA2649961A1 (es) |
DK (1) | DK2418201T3 (es) |
EC (1) | ECSP088876A (es) |
ES (1) | ES2460919T3 (es) |
HR (1) | HRP20140385T1 (es) |
IL (1) | IL194833A0 (es) |
MX (1) | MX2008013982A (es) |
MY (1) | MY144132A (es) |
NO (1) | NO20084567L (es) |
NZ (1) | NZ597177A (es) |
PL (1) | PL2418201T3 (es) |
PT (1) | PT2418201E (es) |
RS (1) | RS53286B (es) |
RU (1) | RU2440984C2 (es) |
SA (1) | SA07280230B1 (es) |
SI (1) | SI2418201T1 (es) |
TW (1) | TWI389889B (es) |
UA (1) | UA96447C2 (es) |
UY (1) | UY30330A1 (es) |
WO (1) | WO2007134034A1 (es) |
ZA (1) | ZA200809284B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7790757B2 (en) | 1998-06-16 | 2010-09-07 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
UA88792C2 (ru) * | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
TWI389889B (zh) * | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
JP2009536665A (ja) | 2006-05-09 | 2009-10-15 | アストラゼネカ・アクチエボラーグ | (2s)−(4e)−n−メチル−5−[3−(5−イソプロポキシピリジン)イル]−4−ペンテン−2−アミンの新規な塩形態 |
PE20081374A1 (es) * | 2006-09-15 | 2008-10-30 | Astrazeneca Ab | Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina |
US20100028447A1 (en) * | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
RU2010107278A (ru) * | 2007-07-31 | 2011-09-10 | Таргасепт, Инк. (Us) | Трансдермальное введение (2s)-(4е)-n-метил-5-(3-(5-изопропоксипиридин)ил)-4-пентен-2-амина |
US20110130428A1 (en) * | 2008-06-11 | 2011-06-02 | Astrazeneca Ab | Sublingual Compositions Comprising (2S) - (4E) -N-Methyl-5- (3- (5-Isopropoxypyridin) YL)-4-Penten-2-Amine |
WO2010080757A2 (en) * | 2009-01-07 | 2010-07-15 | Astrazeneca Ab | Combinations with an alpha-4beta-2 nicotinic agonist |
FR2959107B1 (fr) | 2010-04-23 | 2015-03-27 | Oreal | Unite d'application d'un produit cosmetique |
AU2011256866B2 (en) * | 2010-05-20 | 2014-05-22 | Astrazeneca Ab | New process for the preparation of aryl substituted olefinic amines |
WO2013184732A1 (en) * | 2012-06-06 | 2013-12-12 | Targacept, Inc. | Crystalline (2s)-(4e)-n-methyl-5-[3-(5-isopropoxypyridin)yl]4-penten-2-amine 1,5-naphthalenedisulfonate |
KR101579904B1 (ko) | 2014-09-05 | 2016-01-05 | 동신대학교산학협력단 | 마스카라 |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192946A (en) | 1978-06-29 | 1980-03-11 | Ciba-Geigy Corporation | Process for producing 3-hydroxy-5-halopyridines |
DE3148651A1 (de) | 1981-12-09 | 1983-07-21 | Henkel Kgaa | "haarfaerbemittel, enthaltend 5-halo-2,3-pyridindiole als kupplerkomponente" |
US4582823A (en) | 1984-08-15 | 1986-04-15 | Warner-Lambert Company | Method for treating schizophrenia and medicaments therefor |
WO1989000158A1 (en) | 1987-07-02 | 1989-01-12 | Pfizer Inc. | Bridged-diazabicycloalkyl quinolone carboxylic acids and esters |
IT1226727B (it) | 1988-07-29 | 1991-02-05 | Simes | Farmaci precursori della dopamina. |
US4922901A (en) | 1988-09-08 | 1990-05-08 | R. J. Reynolds Tobacco Company | Drug delivery articles utilizing electrical energy |
DE69016688T2 (de) | 1989-04-20 | 1995-10-05 | Zambon Spa | Dopamin-Medikament-Vorstufe. |
US5187166A (en) | 1990-07-31 | 1993-02-16 | Nisshin Flour Milling Co., Ltd. | Azabicyclo derivatives and their use as antiemetics |
WO1992012122A1 (en) | 1990-12-27 | 1992-07-23 | Abbott Laboratories | N-protected aminoalkylaldehydes |
DE69213559T2 (de) | 1991-05-30 | 1997-02-27 | Mitsui Toatsu Chemicals | Tetravinylpyrazine-Verbindung, Verfahren zur Herstellung derselben und elektrolumineszentes Element und damit hergesteller nichtlinearer optischer Stoff |
US5212188A (en) | 1992-03-02 | 1993-05-18 | R. J. Reynolds Tabacco Company | Method for treatment of neurodegenerative diseases |
IL107184A (en) | 1992-10-09 | 1997-08-14 | Abbott Lab | Heterocyclic ether compounds that enhance cognitive function |
US5852041A (en) | 1993-04-07 | 1998-12-22 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acethylcholine receptors |
US5493026A (en) | 1993-10-25 | 1996-02-20 | Organix, Inc. | Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders |
IT1274018B (it) | 1994-02-23 | 1997-07-14 | Riace Ets | Derivati del 3,8-diazabiciclo(3.2.1.)ottano ad attivita' analgesica |
ES2163506T3 (es) | 1994-06-14 | 2002-02-01 | Pfizer | Derivados de bencimidazolona con actividad dopaminergica central. |
GB2295387A (en) | 1994-11-23 | 1996-05-29 | Glaxo Inc | Quinazoline antagonists of alpha 1c adrenergic receptors |
US5597919A (en) | 1995-01-06 | 1997-01-28 | Dull; Gary M. | Pyrimidinyl or Pyridinyl alkenyl amine compounds |
US5604231A (en) | 1995-01-06 | 1997-02-18 | Smith; Carr J. | Pharmaceutical compositions for prevention and treatment of ulcerative colitis |
US5616707A (en) | 1995-01-06 | 1997-04-01 | Crooks; Peter A. | Compounds which are useful for prevention and treatment of central nervous system disorders |
US5585388A (en) | 1995-04-07 | 1996-12-17 | Sibia Neurosciences, Inc. | Substituted pyridines useful as modulators of acetylcholine receptors |
US5583140A (en) | 1995-05-17 | 1996-12-10 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of central nervous system disorders |
IL118279A (en) | 1995-06-07 | 2006-10-05 | Abbott Lab | Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission |
US5616716A (en) | 1996-01-06 | 1997-04-01 | Dull; Gary M. | (3-(5-ethoxypyridin)yl)-alkenyl 1 amine compounds |
AT403803B (de) | 1996-04-19 | 1998-05-25 | Sanochemia Ltd | Neue benzazepinderivate, diese enthaltende arzneimittel und verwendung derselben zum herstellen von arzneimitteln |
US20020052497A1 (en) | 2000-03-09 | 2002-05-02 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
US5663356A (en) | 1996-04-23 | 1997-09-02 | Ruecroft; Graham | Method for preparation of aryl substituted alefinic secondary amino compounds |
US6979695B2 (en) | 1996-04-23 | 2005-12-27 | Targacept, Inc. | Compounds capable of activating cholinergic receptors |
AU727976B2 (en) | 1996-04-23 | 2001-01-04 | Targacept, Inc. | Pharmaceutical compositions for prevention and treatment of central nervous system disorders |
US5726189A (en) | 1996-05-03 | 1998-03-10 | The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Method for imaging nicotinic acetylcholinergic receptors in the brain using radiolabeled pyridyl-7-azabicyclo 2.2.1!heptanes |
US5861423A (en) | 1997-02-21 | 1999-01-19 | Caldwell; William Scott | Pharmaceutical compositions incorporating aryl substituted olefinic amine compounds |
US5811442A (en) | 1997-02-21 | 1998-09-22 | Bencherif; Merouane | Pharmaceutical compositions for the treatment of conditions associated with decreased blood flow |
DE69804212T2 (de) | 1997-05-08 | 2002-07-25 | Pfizer Products Inc., Groton | Verfahren und zwischenprodukte zur herstellung substituierter indazolderivate |
NZ503520A (en) | 1997-10-27 | 2002-08-28 | Neurosearch As | Heteroaryl or aryl substituted diazacycloalkanes useful as cholinergic ligands at nicotinic acetylcholine receptors |
US6632823B1 (en) | 1997-12-22 | 2003-10-14 | Merck & Co., Inc. | Substituted pyridine compounds useful as modulators of acetylcholine receptors |
US6232316B1 (en) | 1998-06-16 | 2001-05-15 | Targacept, Inc. | Methods for treatment of CNS disorders |
DK1086082T3 (da) | 1998-06-16 | 2004-11-22 | Targacept Inc | Arylsubstituerede olefiniske aminer og deres anvendelse som cholinerge receptoragonister |
US6218383B1 (en) | 1998-08-07 | 2001-04-17 | Targacept, Inc. | Pharmaceutical compositions for the prevention and treatment of central nervous system disorders |
US6337351B1 (en) | 1998-10-22 | 2002-01-08 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6953855B2 (en) | 1998-12-11 | 2005-10-11 | Targacept, Inc. | 3-substituted-2(arylalkyl)-1-azabicycloalkanes and methods of use thereof |
FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
CA2376061A1 (en) | 1999-06-07 | 2000-12-14 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
GB9922271D0 (en) | 1999-09-21 | 1999-11-17 | Zeneca Ltd | Formulation |
US6506769B2 (en) | 1999-10-06 | 2003-01-14 | Boehringer Ingelheim Pharmaceuticals, Inc. | Heterocyclic compounds useful as inhibitors of tyrosine kinases |
WO2001078735A1 (en) | 2000-04-13 | 2001-10-25 | Innovata Biomed Limited | Medicaments for treating respiratory disorders comprising formoterol and fluticasone |
US6432954B1 (en) | 2000-07-14 | 2002-08-13 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
US6743812B1 (en) | 2000-07-14 | 2004-06-01 | Targacept, Inc. | Pharmaceutical compositions and methods for use |
PL220721B1 (pl) | 2001-03-29 | 2015-12-31 | Lilly Co Eli | Związki będące pochodnymi N-(indolilo-2-etylo) benzyloaminy, kompozycja farmaceutyczna oraz zastosowanie |
GB2381750A (en) | 2001-10-10 | 2003-05-14 | Inspire Pharmaceuticals Inc | Treatment for enhancing joint lubrication |
NZ554913A (en) | 2001-12-14 | 2009-01-31 | Targacept Inc | Methods and compositions for the treatment of central nervous system disorders |
JP2006512280A (ja) | 2002-03-27 | 2006-04-13 | スミスクライン・ビーチャム・コーポレイション | 化合物および方法 |
US20040044023A1 (en) | 2002-08-30 | 2004-03-04 | Marc Cantillon | Compositions and methods for treating or preventing memory impairment |
US20050203130A1 (en) | 2003-12-02 | 2005-09-15 | Erik Buntinx | Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists |
CA2549638A1 (en) | 2003-12-23 | 2005-07-14 | Pfizer Products Inc. | Therapeutic combination for cognition enhancement and psychotic disorders |
US20050171088A1 (en) | 2004-01-30 | 2005-08-04 | Astrazeneca Ab | Treatment of psychoses with dibenzothiazepine antipsychotic |
EP1730100A1 (en) | 2004-03-29 | 2006-12-13 | MediQuest Therapeutics, Inc. | Polyamine analogs that activate antizyme frameshifting |
JP4148199B2 (ja) | 2004-07-30 | 2008-09-10 | 松下電工株式会社 | 電気かみそり |
US7537590B2 (en) | 2004-07-30 | 2009-05-26 | Microchips, Inc. | Multi-reservoir device for transdermal drug delivery and sensing |
EP1802258A4 (en) | 2004-09-13 | 2015-09-23 | Chrono Therapeutics Inc | BIOSYNCHRONE TRANSDERMAL MEDICINES |
UA88792C2 (ru) | 2004-11-10 | 2009-11-25 | Таргасепт, Інк. | Гидроксибензоатные соли метаникотиновых соединений |
US7459469B2 (en) * | 2004-11-10 | 2008-12-02 | Targacept, Inc. | Hydroxybenzoate salts of metanicotine compounds |
TWI389889B (zh) | 2006-05-09 | 2013-03-21 | Targacept Inc | (2s)-(4e)-n-甲基-5-〔3-(5-異丙氧基吡啶)基〕-4-戊烯-2-胺之新穎多晶型 |
JP2009536665A (ja) | 2006-05-09 | 2009-10-15 | アストラゼネカ・アクチエボラーグ | (2s)−(4e)−n−メチル−5−[3−(5−イソプロポキシピリジン)イル]−4−ペンテン−2−アミンの新規な塩形態 |
US20080138416A1 (en) | 2006-06-13 | 2008-06-12 | Fmc Biopolymer As | Method and systems for using biopolymer-based beads and hydrogels |
PE20081374A1 (es) | 2006-09-15 | 2008-10-30 | Astrazeneca Ab | Combinacion que comprende un agente antipsicotico y (2s)-(4e)-n-metil-5-[3-(5-isopropoxipiridin)il]-4-penten-2-amina |
US20080167286A1 (en) | 2006-12-12 | 2008-07-10 | Abbott Laboratories | Pharmaceutical compositions and their methods of use |
US20100028447A1 (en) | 2007-01-22 | 2010-02-04 | Targacept, Inc. | Intranasal, Buccal, And Sublingual Administration Of Metanicotine Analogs |
-
2007
- 2007-04-27 TW TW096115162A patent/TWI389889B/zh not_active IP Right Cessation
- 2007-05-07 AR ARP070101972A patent/AR060786A1/es not_active Application Discontinuation
- 2007-05-07 UY UY30330A patent/UY30330A1/es not_active Application Discontinuation
- 2007-05-08 PL PL11167528T patent/PL2418201T3/pl unknown
- 2007-05-08 SA SA07280230A patent/SA07280230B1/ar unknown
- 2007-05-08 MY MYPI20084443A patent/MY144132A/en unknown
- 2007-05-08 CN CNA2007800168072A patent/CN101472893A/zh active Pending
- 2007-05-08 PT PT111675286T patent/PT2418201E/pt unknown
- 2007-05-08 EP EP07783431A patent/EP2021326A1/en not_active Withdrawn
- 2007-05-08 MX MX2008013982A patent/MX2008013982A/es active IP Right Grant
- 2007-05-08 KR KR1020087027218A patent/KR20090005369A/ko active IP Right Grant
- 2007-05-08 RU RU2008148325/04A patent/RU2440984C2/ru not_active IP Right Cessation
- 2007-05-08 JP JP2009503340A patent/JP4477097B2/ja not_active Expired - Fee Related
- 2007-05-08 RS RS20140212A patent/RS53286B/en unknown
- 2007-05-08 AU AU2007249485A patent/AU2007249485B2/en not_active Ceased
- 2007-05-08 CA CA002649961A patent/CA2649961A1/en not_active Abandoned
- 2007-05-08 DK DK11167528.6T patent/DK2418201T3/da active
- 2007-05-08 NZ NZ597177A patent/NZ597177A/xx not_active IP Right Cessation
- 2007-05-08 SI SI200731433T patent/SI2418201T1/sl unknown
- 2007-05-08 WO PCT/US2007/068446 patent/WO2007134034A1/en active Application Filing
- 2007-05-08 ES ES11167528.6T patent/ES2460919T3/es active Active
- 2007-05-08 EP EP11167528.6A patent/EP2418201B1/en active Active
- 2007-05-08 BR BRPI0709781-6A patent/BRPI0709781A2/pt not_active IP Right Cessation
- 2007-05-08 US US11/745,682 patent/US8461344B2/en not_active Expired - Fee Related
- 2007-08-05 UA UAA200814135A patent/UA96447C2/ru unknown
-
2008
- 2008-10-22 IL IL194833A patent/IL194833A0/en unknown
- 2008-10-29 ZA ZA200809284A patent/ZA200809284B/xx unknown
- 2008-10-30 NO NO20084567A patent/NO20084567L/no not_active Application Discontinuation
- 2008-11-07 EC EC2008008876A patent/ECSP088876A/es unknown
-
2009
- 2009-10-29 US US12/608,450 patent/US20100048643A1/en not_active Abandoned
-
2013
- 2013-05-14 US US13/893,408 patent/US20130310425A1/en not_active Abandoned
-
2014
- 2014-04-28 HR HRP20140385TT patent/HRP20140385T1/hr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200809284B (en) | Polymorph forms of (2S) - (4E) -N-Methyl-5- )3-Isopropoxypyridin) YL]-4-Penten-2-amine for the treatment of central nervous system disorders | |
EP1981526A4 (en) | ADIPONECTIN FOR THE TREATMENT OF VARIOUS DISORDERS | |
IL187168A0 (en) | Improved nanobodiestm for the treatment of aggregation-mediated disorders | |
EP1976377A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
ZA200608628B (en) | Substituted morpholine compounds for the treatment of central nervous system disorders | |
EP1983972A4 (en) | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | |
EP2083857A4 (en) | METHOD FOR TREATING INTERFERENCE IN CONNECTION WITH MICA | |
IL195203A0 (en) | Compounds for the treatment of metabolic disorders | |
IL192636A0 (en) | Aryl-isoxazol-4-yl-imidazo[1,2-a]pyridine useful for the treatment of alzheimer's disease via gaba receptors | |
ZA200903889B (en) | Process for the synthesis of moxifloxacin hydrochloride | |
PL1993589T3 (pl) | Sposoby leczenia chorób neurologicznych | |
IL192852A0 (en) | Compounds for the treatment of metabolic disorders | |
PL1841433T3 (pl) | Kompozycja do leczenia zaburzeń ośrodkowego układu nerwowego | |
ZA200806455B (en) | Use of 2-imidazoles for the treatment of CNS disorders | |
PL1824384T3 (pl) | System do diagnostyki zaburzeń pnia mózgu | |
IL192877A0 (en) | Use of 2-imidazoles for the treatment of cns disorders | |
IL189524A0 (en) | Imidazole compounds for the treatment of neurological disorders | |
IL192851A0 (en) | Compounds for the treatment of metabolic disorders | |
PL1982178T3 (pl) | Sposoby leczenia zaburzeń afektywnych | |
IL195392A0 (en) | Compounds for the treatment of metabolic disorders | |
HK1129112A1 (en) | 2 -alkyl- indazole compounds for the treatment of certain cns-related disorders | |
IL198967A0 (en) | Dialkylamino alkyl esters of pivagabine as medicaments for the treatment of central nervous system disorders | |
ZA200807678B (en) | Meridamycin analogues for the treatment of neurodegenerative disorders | |
GB0604772D0 (en) | Use of substituted amine compounds for the treatment of food related disorders | |
IL192982A0 (en) | Compounds for the treatment of metabolic disorders |